Eli Lilly's Mazdutide Shows Promise in Alcohol Use Disorder Study
Eli Lilly is conducting a proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder.
Indication
Clinical and regulatory intelligence for Alcohol Use Disorder with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
The NIAAA is testing a new assessment tool called the Addictions Neuroclinical Assessment (ANA) to better understand alcohol use disorder.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.